Timothy Truong Phamduy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Timothy Truong Phamduy has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Alexander H. Hogan
Department of Pediatrics, University of Connecticut School of Medicine, Farmington, Connecticut
1 shared publicationDouglas Morris Young
From 7th Medical Group, Dyess Air Force Base, US Air Force, Abilene TX (TTP, DMY); Abilene Dermatology & Skin Surgery Center, Abilene TX (PBR)
1 shared publicationJesse Sturm
Department of Pediatrics, University of Connecticut School of Medicine, Farmington, Connecticut
1 shared publicationJuan C. Salazar
Department of Pediatrics, University of Connecticut School of Medicine, Farmington, Connecticut
1 shared publicationKatherine W. Herbst
Division of Research, Connecticut Children’s Medical Center
1 shared publicationMichael Brimacombe
Division of Research, Connecticut Children’s Medical Center
1 shared publication
Latest Publications
- Open Access
- 10 August 2021
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 40 (11) , e407-e412
Kawasaki Disease Hospitalizations in the United States 2016–2020: A Comparison of Before and During the Coronavirus Disease 2019 Era
Background: Kawasaki disease (KD) is an acute vasculitis of young children. A comparison of US hospitalization rates and epidemiologic features of KD in 2020 to those of precoronavirus disease years has yet to be reported. Methods: Using a large, inpatient database, we conducted a retrospective cohort study and analyzed data for patients with (1) diagnosis coding for KD, (2) IV immunoglobulin treatment administered during hospitalization and (3) discharge date between January 1, 2016, and December 30, 2020. Severe cases were defined as those requiring adjunctive therapy or IV immunoglobulin–resistant therapy. Results: The annual number of KD hospitalizations were stable from 2016 to 2019 (n = 1652, 1796, 1748, 1692, respectively) but decreased in 2020 (n = 1383). KD hospitalizations demonstrated seasonal variation with an annual peak between December and April. A second peak of KD admissions was observed in May 2020. The proportion of KD cases classified as severe increased to 40% in 2020 from 33% during the years 2016–2019 (P < 0.01). Median age in years increased from 2.9 in subjects hospitalized from 2016 to 2019 to 3.2 in 2020 (P = 0.002). Conclusions: Compared with the previous 4 years, the annual number of pediatric KD admissions decreased, and children discharged with diagnostic codes for KD in 2020 were generally older and more likely to have severe morbidity possibly reflective of misdiagnosed multisystem inflammatory syndrome in children. Clinicians should be wary of a possible rise in KD rates in the postcoronavirus disease 2019 era as social distancing policies are lifted and other viruses associated with KD return.
- 10 August 2021
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 40 (11) , e407-e412
Open AccessKawasaki Disease Hospitalizations in the United States 2016–2020: A Comparison of Before and During the Coronavirus Disease 2019 Era
Background: Kawasaki disease (KD) is an acute vasculitis of young children. A comparison of US hospitalization rates and epidemiologic features of KD in 2020 to those of precoronavirus disease years has yet to be reported. Methods: Using a large, inpatient database, we conducted a retrospective cohort study and analyzed data for patients with (1) diagnosis coding for KD, (2) IV immunoglobulin treatment administered during hospitalization and (3) discharge date between January 1, 2016, and December 30, 2020. Severe cases were defined as those requiring adjunctive therapy or IV immunoglobulin–resistant therapy. Results: The annual number of KD hospitalizations were stable from 2016 to 2019 (n = 1652, 1796, 1748, 1692, respectively) but decreased in 2020 (n = 1383). KD hospitalizations demonstrated seasonal variation with an annual peak between December and April. A second peak of KD admissions was observed in May 2020. The proportion of KD cases classified as severe increased to 40% in 2020 from 33% during the years 2016–2019 (P < 0.01). Median age in years increased from 2.9 in subjects hospitalized from 2016 to 2019 to 3.2 in 2020 (P = 0.002). Conclusions: Compared with the previous 4 years, the annual number of pediatric KD admissions decreased, and children discharged with diagnostic codes for KD in 2020 were generally older and more likely to have severe morbidity possibly reflective of misdiagnosed multisystem inflammatory syndrome in children. Clinicians should be wary of a possible rise in KD rates in the postcoronavirus disease 2019 era as social distancing policies are lifted and other viruses associated with KD return.
- 23 February 2021
- Published by American Board of Family Medicine (ABFM) in The Journal of the American Board of Family Medicine
- Vol. 34 (Supplement) , S183-S185
Localized Scarlatiniform Rash of the Ears and Antecubital Fossa in COVID-19
The worldwide spread of the novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to a global pandemic since its identification in Wuhan, China in December 2019.1 Few cases of COVID-19-associated dermatologic manifestations have been reported in the literature to date. This report describes the clinical features of a localized pruritic scarlatiniform rash of the ears and antecubital fossa on defervescence in a 29-year-old patient with COVID-19. Our case stands to further illuminate the dermatologic manifestations of this novel disease.
- 23 February 2021
- Published by American Board of Family Medicine (ABFM) in The Journal of the American Board of Family Medicine
- Vol. 34 (Supplement) , S183-S185
Localized Scarlatiniform Rash of the Ears and Antecubital Fossa in COVID-19
The worldwide spread of the novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to a global pandemic since its identification in Wuhan, China in December 2019.1 Few cases of COVID-19-associated dermatologic manifestations have been reported in the literature to date. This report describes the clinical features of a localized pruritic scarlatiniform rash of the ears and antecubital fossa on defervescence in a 29-year-old patient with COVID-19. Our case stands to further illuminate the dermatologic manifestations of this novel disease.